Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 9, 2025Experimental OncologyOpen Access

Molecular Markers in Predicting the Outcome of Diffuse Glioma Grade 4 Treatment

View Full Paper
Ask AI
Bookmark
Share

Authors

OGOleksandr GlavatskyiIVI. G. VasylievaТМТ. А. Малышева

Discussion

Loading...

Member takes

Overview

Observational analysis evaluates mgmt expression and idh1/2 variants in glioblastoma patients, suggesting targeted therapy benefits.

Key Points

  • Patients with low mgmt gene expression (<1000 copies) exhibit better treatment outcomes with temozolomide.
  • MGMT RNA copies ranged dramatically from 1.7 to 88,270.2 copies per 1000 cells in glioblastoma samples.
  • IDH1/2 status was wild type in 36 patients, with 3 cases identified as heterozygous.
  • Assessing mgmt levels may predict overall survival and recurrence risk in glioblastoma patients.

Cite This Study

Glavatskyi et al. (2025) studied this question.

synapsesocial.com/papers/68e7ba40ccde5f1021f64c5chttps://doi.org/10.15407/exp-oncology.2025.02.216
View Full Paper
Ask AI
Bookmark
Share